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Background
Since 2002 people with rheumatic diseases have partici-
pated in the bi-annual 5-day international conference
and workshop on Outcome Measures in Rheumatology
(OMERACT), which uses evidence-based consensus to
determine core outcome measures for clinical trials of
rheumatological conditions. Patients contribute their
perspective and collaborate as equal partners in all con-
ference sessions. In all, 46 patients with 7 different con-
ditions from 12 countries have participated in
O M E R A C T .W i t ht h eh e l po fp r o f e s s i o n a l st h e yh a v e
organized themselves and developed various support
mechanisms.
Methods
The authors have called on their personal experiences of
OMERACT, a review of OMERACT publications and
discussions with long-term OMERACT participants in
setting out results and drawing conclusions.
Results
The effect of patient involvement has been threefold:
First, the OMERACT research agenda has been
enriched by the identification of new domains that are
relevant from a patient perspective. The most important
example has been the increased efforts to gain more
knowledge about the nature and impact of fatigue in
rheumatoid arthritis. Fatigue has been added to the
rheumatoid arthritis core-set and is now widely mea-
sured as an important outcome in clinical trials.
Second, involvement of patients in the structure of
the meetings has given insights into barriers to patient
participation and to ways of facilitating the incorpora-
tion of the patient perspective in outcome research.
Before the start of the conference patient participants
need appropriate information about the objective and
program of the conference and the expected contribu-
tions. They need training, support and encouragement
to be able to fully collaborate in all parts of the pro-
gram. And challenges like the patient-doctor relation-
ship, ethics, confidentiality and communication need
to be addressed.
Third, OMERACT has set a standard for patient
involvement in health outcome research that has led to
new local, national and international, initiatives.
Conclusions
Building the involvement of patients directly into the
OMERACT meeting program has significantly contribu-
ted to the success of this biannual conference. It has
broadened the research agenda of OMERACT, it has
had a major spin off on patient involvement in research
projects on a national level and it has set a new stan-
dard for patient involvement in health outcome
research. However, there remains the challenge of fully
developing patient participation in the research working
groups that meet between the conferences.
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